Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
4D Molecular Therapeutics, Inc.FDMT-9.3644.411.49-1.88-24.06%-10.88%31.56$22.05$25.078,304$16.24

Detail of 4D Molecular Therapeutics, Inc.

 
CEO
Dr. David H. Kirn M.D.
Employees
201
Industry
Biotechnology
Sector
Healthcare
Market cap
$898M

Company details

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Revenue
Revenue (Rev)
$20.22M
4D Molecular Therapeutics, Inc.
FDMT • XNGS • US
$16 .24
+0.69 (4.43%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.74
Margin profit
0.00%
52 week low
$9.74
52 week high
$35.869999
50-day simple moving average
$15.52
200-day simple moving average
$16.43
Percent held by insiders
3.48%
Percent held by institutions
112.50%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
FDMT +4.43%
eps change
FDMT 0.00%